Form 4: GeneDx CFO Sells Shares for Tax Obligations

GeneDx Holdings Corp.'s CFO, Kevin Feeley, sold 378 shares of Class A Common Stock to cover tax withholding obligations related to RSU vesting.

Summary

• Kevin Feeley, Chief Financial Officer of GeneDx Holdings Corp. (WGS), reported transactions involving the company's Class A Common Stock.
• On September 1, 2025, 717 Restricted Stock Units (RSUs) vested and converted into Class A Common Stock at a price of $0 per share.
• Following this vesting, Feeley's direct beneficial ownership of Class A Common Stock was 4,474 shares.
• On September 2, 2025, Feeley sold 378 shares of Class A Common Stock at a weighted average price of $125.8096 per share.
• These sales were non-discretionary, executed to cover tax withholding obligations associated with the vesting and settlement of RSUs.
• After the sale, Feeley's direct beneficial ownership of Class A Common Stock decreased to 4,096 shares.
• Additionally, Feeley beneficially owns 134,292 RSUs and options to purchase 27,152 shares of Class A Common Stock, which vest according to their respective terms.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine, non-discretionary transaction by an insider to cover tax obligations related to equity compensation, rather than a discretionary sale or purchase based on market outlook.

Positives

• The vesting of Restricted Stock Units (RSUs) indicates the fulfillment of compensation agreements for the Chief Financial Officer.

Negatives

• The sale of shares by an insider, even for tax purposes, reduces their direct equity stake in the company.

Future Outlook

The remaining Restricted Stock Units and options held by the Chief Financial Officer are subject to a vesting schedule, with RSUs vesting quarterly over a four-year period commencing December 1, 2022, contingent on continued service.

Management Comments

• The sales reported represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs.
• The sales were to satisfy tax withholding obligations to be funded by a 'sell to cover' transaction and do not represent a discretionary transaction by the Reporting Person.

Industry Context

This Form 4 filing details a routine insider transaction related to equity compensation and tax obligations, which is a common occurrence across all industries for executives receiving stock-based awards. It does not provide specific insights into broader industry trends for the biotechnology or diagnostics sector.

Comparison to Industry Standards

• The 'sell to cover' transaction is a standard and widely accepted practice for executives to manage tax liabilities arising from the vesting of restricted stock units or the exercise of stock options. This mechanism is common across publicly traded companies, including those in the biotechnology and healthcare sectors, and is not indicative of a discretionary sale based on market sentiment.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes by an executive, not a signal of management's discretionary view on the company's prospects.
• Employees: No direct impact mentioned.

Next Steps

• Continued vesting of the remaining 134,292 Restricted Stock Units and 27,152 options according to their respective terms and schedules.

Key Dates

Keywords

GeneDx Holdings Corp, WGS, Kevin Feeley, CFO, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Sell to Cover, Tax Withholding, Equity Compensation